Kuala Lumpur
Kuala Lumpur
Kuala Lumpur, Kuala Lumpur, Malaysia80 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-10-07 | NCT06091865 | |
| A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, urinary system disorder | Recruiting | Phase 3 | 2026-10-05 | NCT04557462 | |
| A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, anemia, bone marrow disorder, hematologic disorder, primary myelofibrosis | Recruiting | Phase 3 | 2026-10-01 | NCT07623161 | |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | cardiovascular disorder, heart disorder, heart failure | Active, not recruiting | Phase 3 | 2026-10-01 | NCT06200207 | |
| A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Urogenital Diseases, kidney disorder, urinary system disorder | Recruiting | Phase 3 | 2026-09-30 | NCT06963827 | |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-30 | NCT06765109 | |
| Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension) | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Recruiting | Phase 3 | 2026-09-28 | NCT06711887 | |
| Mechanism of FODMAP Restriction on FGID Patients | Digestive System Diseases, colonic disorder, digestive system disorder, functional colonic disease, intestinal disorder, irritable bowel syndrome | Recruiting | Not applicable | 2026-09-25 | NCT07000227 | |
| A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-09-25 | NCT05920356 | |
| Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD | Mixed Dyslipidemia; Primary Hypercholesterolemia | Active, not recruiting | Not stated | 2026-09-24 | NCT05399992 | |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-23 | NCT07085767 | |
| A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Advanced Non-small Cell Lung Cancer, HER2 Mutation | Recruiting | Phase 3 | 2026-09-23 | NCT06452277 | |
| A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Hemic and Lymphatic Diseases, anemia, bone marrow disorder, hematologic disorder, myelodysplastic syndrome | Recruiting | Phase 3 | 2026-09-18 | NCT07422480 | |
| Efficacy and Safety of Intrapleural Fibrinolytic Therapy in Tuberculous Pleural Effusion Versus Non-Tuberculous Pleural Infection | Tuberculous Pleural Effusion | Not yet recruiting | Not stated | 2026-09-16 | NCT07823075 | |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder | Recruiting | Phase 3 | 2026-09-15 | NCT06492616 | |
| Safety and Feasibility of Medical Thoracoscopy Using Single-use Flexible Bronchoscope Versus SemiRigid Pleuroscope in Pleural Effusion | Neoplasms by Site, Pleural Effusion, Pleural Effusion, Malignant, Thoracic Neoplasms, myeloproliferative disorder, chronic, with eosinophilia, neoplasm, pleural disorder, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Not applicable | 2026-09-11 | NCT07726784 | |
| A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-09-11 | NCT06646276 | |
| Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, Schizophrenia, Treatment-Resistant, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-10 | NCT07184619 | |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | cardiovascular disorder, heart disorder, heart failure | Recruiting | Phase 3 | 2026-09-10 | NCT06008197 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04822181 | |
| NeoSpHb Study: Can a Painless Device Detect Anaemia in Babies Without Blood Tests? A Study in the Neonatal Intensive Care Unit (NICU) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Infant, Newborn, Diseases, anemia, hematologic disorder, neonatal anemia | Not yet recruiting | Not applicable | 2026-08-26 | NCT07788703 | |
| A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-08-26 | NCT07128199 | |
| A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | Bacterial Infections and Mycoses, Infections, Skin and Connective Tissue Diseases, Suppuration, bacterial infectious disease, dermatitis, hidradenitis, hidradenitis suppurativa, skin disease caused by bacterial infection, skin disorder, skin disorder caused by infection, sweat gland disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT06840392 | |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT05126277 |